Evaluation of the Medical Device Vagitab - T As Adjuvant Therapy in Patients with Bacterial Vaginosis.

Not Applicable

Not yet recruiting

• Conditions: Bacterial Vaginosis (BV); Recurrent Bacterial Vaginosis

• Registration Number: NCT06725888
• Lead Sponsor: S.I.I.T. Srl

Brief Summary

This clinical trial is looking at how well and safely the vaginal administration of Vagitab-T works . Vagitab-T is already on the market in several countries in Europe as a medical device.

The main goals of this trial are to see if the recurrence rate of bacterial vaginosis goes down during the study, if it helps balance the altered vaginal flora during antibiotic treatment, if it improves vaginal secretions, and if vaginal microflora return to normal. We'll also ask the participants about their quality of life and whether they think the treatment is safe.

All 30 women will get the same treatment, and there's no comparison group. They'll be treated with Vagitab-T vaginal tablets for three monthly cycles. Also, metronidazole will be taken at the start of the study for seven days.

Participants will sign an informed written consent and we'll visit them at the start (day 0) and end (day 90) of the study. In addition, we'll call them during each of the three cycles of treatment.

Detailed Description

Bacterial vaginosis (BV) affects 20-25% of the general population and is the most common cause of vaginal discharge. It is a polymicrobial disease that typically manifests when the protective antibacterial activity of vaginal lactobacilli is impaired, allowing for the overgrowth of anaerobic bacteria and other pathogens, including Gardnerella vaginalis and Mycoplasma hominis. The term "recurrent bacterial vaginosis" (RBV) is used to describe a condition characterized by two to three episodes of bacterial vaginosis (BV) per year. The recurrence rates are as high as 35% within one month, 50% within three months, and 70% within 12 months.

Given the multiplicity of potential risk factors, the aetiology and pathogenesis of BV remain incompletely understood, and the efficacy of current treatment regimens is variable, resulting in high recurrence rates.

A review of the medical literature reveals that no recommended gold-standard therapies have been established, and that the treatments are not always effective, resulting in high recurrence rates. Consequently, the objective of clinical research is to identify safe and effective products that do not disrupt the delicate equilibrium of the vaginal microbiota. It is imperative to commence treatment promptly following antibiotic therapy to impede the formation of a vaginal biofilm.

Recent published reviews and meta-analyses have demonstrated the efficacy of probiotic preparations in the treatment and prevention of BV. These studies suggest that the amount of exogenously applied Lactobacilli may influence the effectiveness of the treatment. The rationale for testing Vagitab-T as an adjuvant product in the treatment of BV and in preventing the recurrences, and consequently in reducing the use of antibiotics without causing resistance, is based primarily on the synergistic association of functional ingredients and mechanism of action. Vagitab-T is a topical intravaginal tablet formulation that employs several components, including tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350, employed for the prevention and treatment of vaginal infections of bacterial or mycotic origin, for the facilitation of the regrowth of a healthy microflora, and for the reduction of the symptoms of vaginal dryness. Vagitab-T is classified as a medical device due to the mechanisms of action, which do not involve the use of biocidal, immunostimulant, or pharmacological effects. Additionally, these mechanisms do not interfere with the functions of host cells.

This open, non-randomized trial will be conducted at two clinical sites in Romania. The objective is to evaluate the efficacy, safety, and tolerability of Vagitab-T vaginal tablets in women diagnosed with bacterial vaginosis (BV) according to the Amsel criteria and with a history of recurrent BV (RBV), defined as at least two episodes per year. The patients will be treated with Vagitab-T vaginal tablets for three monthly cycles of 10 days each, with concurrent administration of metronidazole for seven days. The study duration for each patient is 90 days. The sample size has been determined to be 30 evaluable patients, and the investigators intend to screen 33 patients to achieve this number (allowing for three screening failures). The main objectives of the study will be the evaluation of the reduction of recurrence rate of Bacterial Vaginosis during a 3-month cycle treatment, the adjuvant activity in rebalancing the altered vaginal flora during the antibiotic treatment period, and in improving the fluidity of vaginal secretions. Additional objectives will be the evaluation of the rate of return to normality of vaginal microflora, the quality of life, and the safety evaluation.

Study Timeline

• Status Verified: 2024-11
• Study First Submitted: 2024-11-20
• Study First Submitted QC: 2024-12-05
• Last Update Submitted: 2024-12-05
• Study First Posted: 2024-12-10
• Last Update Posted: 2024-12-10
• Study Start: 2024-12-15
• Primary Completion: 2025-05-30
• Study Completion: 2025-07-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

• Female patients aged from 18 to 65 years (inclusive).
• Patients affected at enrolment by BV diagnosed according to Amsel criteria, candidate to start an antibiotic therapy with metronidazole.
• Patient with a medical history of RBV (at least 2 episodes of BV in the last 12 months including the current episode).
• Patients who are, in the opinion of the Investigator, able to understand the study, cooperate with the study procedures and attend all the study visits.
• Patients who have given their written informed consent to participate in the study.

Exclusion Criteria

• Patient with a medical history of HIV or any other immunodeficiency.
• Patients working as sex workers.
• Patients with known allergies or intolerance / hypersensitivity to the tested medical device and its components.
• Patients with concomitant menstrual bleeding at baseline.
• Time between the last day of last menses and treatment with metronidazole ≤ 3 days.
• Pregnant, lactating, and lactating amenorrhoeic patients and patients of childbearing potential who are planning a pregnancy or unwilling to use appropriate methods of contraception during the study
• Concomitant use of vaginal tampons.
• Concomitant administration of etonogestrel/ethinyl estradiol vaginal rings or of intrauterine devices.
• Concomitant use of oral or vaginal antibiotic therapy (apart from metronidazole) or any other vaginal therapies or treatment (such as douching, spermicide).
• Concomitant use of oral or vaginal probiotics.
• Patients with any other medical condition that, in the opinion of the Investigator, would compromise participation or be likely to lead to hospitalization during the study.
• Concomitant or previous (in the previous 30 days) participation in any other interventional clinical trials

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Bacterial Vaginosis (BV) Recurrence	90 days	BV recurrences will be clinically diagnosed according to the Amsel criteria, which define the presence of BV based on the presence of at least 3 of the following 4 criteria: vaginal pH \> 4.5, clue cells on saline wet mount, release of a fishy amine odor when 10% potassium hydroxide is added to a drop of vaginal discharge ("whiff test"), and/or characteristic thin, homogeneous vaginal discharge. The number of BV recurrences in the enrolled population during the 3 months of the study will be compared to the average untreated recurrence rate reported in the medical literature (approximately 50% within 3 months).

Secondary Outcome Measures

Name	Time	Method
Vaginal Lactobacillus Microbiota	90 days	Mucus and cell samples collected from the endocervix by swabbing will be evaluated by optical microscopy using the following classification: normal (numerous pleomorphic lactobacilli, no other bacteria or clue cells or hyphae); partially impaired (population of lactobacilli severely reduced); pathological (lactobacilli severely reduced or absent due to overgrowth of other bacteria or clue cells (\>20%) or hyphae).; Change evaluated from baseline to 90 days (end of study)
Vaginal Discharge	90 days	It is evaluated over the past 24 hours using the following 3-point scale: 0 = absent or physiological; 1 = mildly abnormal (abnormal amount with normal color and type); 2 = abnormal amount and abnormal color and type.
Burning	90 days	It is rated over the past 24 hours using the following 5-point scale: 0 = not present; 1 = mild; 2 = moderate; 3 = severe; 4 = unbearable
Erythema	90 days	It is rated on the following 5-point scale: 0 = no symptoms; 1 = mild; 2 = moderate; 3 = severe: 4 = very severe.
Dyspareunia	90 days	It is evaluated using the following dichotomic scale: 0 = absent; 1 = present.
Quality of Life (QoL)	90 days	Quality of Life (QoL) is assessed using the SF-12 questionnaire, comprising twelve questions pertaining to the individual's physical and mental health. Each question is scored from 1 to 5, with the total score ranging from 0 to 100. Higher scores indicate better health functioning.
Investigator Overall Performance	90 days	It is evaluated using the Investigator Global Assessment of Performance Questionnaire (IGAP). The questionnaire evaluates treatment performance using the following 4-point scale: 1 = very good performance; 2 = good performance; 3 = fair performance; 4 = poor performance.
Patient Overall Performance	90 days	It is assessed by the Patient Global Assessment of Performance Questionnaire (PGAP). The questionnaire, evaluates treatment performance using the following 4-point scale 1 = very good performance; 2 = good performance; 3 = fair performance; 4 = poor performance
Investigator Overall Safety	90 days	The assessment is conducted using the Investigator Global Assessment of Safety Questionnaire (IGAS). The questionnaire assesses the safety of the treatment in question using a 4-point scale: 1 = very good safety; 2 = good safety; 3 = fair safety; 4 = poor safety.
Patient Overall Safety	90 days	The assessment is conducted using the Patient Global Assessment of Safety Questionnaire (PGAS). The questionnaire evaluates the safety of the treatment in question using a 4-point scale: 1 = Excellent safety; 2 = Good safety; 3 = Fair safety; 4 = Poor safety.
Serious Adverse Device Effects / Serious Adverse Events /Adverse Device Effects/ Adverse Events	90 days	The number of participants with treatment-related adverse events will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 6.0
Fluidity of vaginal secretion	90 days	The subjective rating of vaginal secretion fluidity is determined by patients using a Visual Analog Scale (VAS). The VAS is a horizontal line, 100 mm in length. The left end of the line is marked "0," indicating minimum fluidity, while the right end is marked "100," indicating maximum fluidity. Patients are instructed to mark the point on the line that best represents the fluidity of their secretions. The VAS score is determined by measuring millimeters from the left end of the line to the point marked by the patient. Change is assessed from baseline to 90 days (end of study).
Normality of vaginal flora	90 days	It is evaluated by the investigators using the Nugent score. The vaginal smears are plated on a microscope slide in oil immersion and at least 10 high power fields are examined for three bacterial morphotypes: Lactobacillus, Gardnerella, and curved gram rods. Each of these three categories is given a score based on the number of bacteria counted. These three scores are then added together to give a total score from 0 - 10. The score is as follows: 0-3: negative for BV, 4-6: intermediate, and 7+: positive for BV. Samples analysis is performed in a central laboratory.; Change will be assessed from baseline to 90 days (end of study).

Trial Locations

Locations (1)

Gyniclinique - Strada Johann Wolfgang von Goethe nr. 2; 🇷🇴 Timisoara, Timis, Romania